Processa Pharmaceuticals Inc SEC Filings

Form 4/A filed for Processa Pharmaceuticals, Inc. (PCSA) amends earlier reporting. The reporting person is Sian Bigora, identified as Chief Development Officer and Director. The earliest transaction date reported is 07/24/2025, with an amendment date of 07/28/2025 and a signature entry dated 09/18/2025. The filing shows a disposition of 33,626 shares of common stock and continued beneficial ownership of 6,668 shares held indirectly through CorLyst, LLC. The amendment states it was filed to retract a prior Form 4 that was filed in error. The document discloses insider role, the specific share disposition, and the indirect ownership vehicle.

Processa Pharmaceuticals director Khoso Baluch amended a prior Form 4 to correct reported insider holdings and retract an earlier erroneous filing. The amendment discloses a restricted stock grant of 31,206 shares that vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, and states 36,275 shares as the amount of common stock beneficially owned following the reported transactions. The filing identifies the reporting person as a director and shows an earliest transaction date of 07/24/2025, an amendment date of 07/28/2025, and a signature date of 09/18/2025. The amendment states it was filed to correct the beneficially owned shares reported on a Form 4 filed September 18, 2024, and to retract that prior Form 4 which was filed in error.

Armistice Capital, LLC and Steven Boyd report a passive stake in Processa Pharmaceuticals (PCSA). Together they disclose beneficial ownership of 2,644,376 shares, representing 4.99% of the common stock, with shared voting and dispositive power over those shares and no sole voting or dispositive power. Armistice Capital is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., and Mr. Boyd is the managing member of Armistice Capital. The filing states the position is held in the ordinary course of business and not to influence control. The filing is a joint Schedule 13G/A amendment dated August 14, 2025.

Processa Pharmaceuticals (PCSA) disclosed that two reporting persons—CVI Investments, Inc. and Heights Capital Management, Inc.—beneficially own 4,471,067 shares, representing 9.9% of the company’s common stock. The reported position consists of shares issuable upon exercise of warrants and is subject to an exercise limitation so that ownership would not exceed 9.99%. Heights Capital Management serves as investment manager to CVI Investments and may exercise shared voting and dispositive power over the reported shares, while each reporting person disclaims other beneficial ownership except for pecuniary interest. The filing names the total outstanding share count as 40,284,356 as of June 30, 2025.

Processa Pharmaceuticals (Common Stock) disclosure shows HX Entertainment Ltd acquired 5,467,181 shares, representing approximately 10.9% of the outstanding common stock, for an aggregate purchase price of about $1,243,784 at roughly $0.2275 per share. The shares were acquired under a Securities Purchase Agreement as restricted securities and HX reports sole voting and dispositive power over all shares. HX states funds came from its working capital and investment funds, with no borrowing or pledging of issuer securities. HX describes the purchase as a strategic investment and reserves the right to acquire or dispose of additional securities, engage with management or the board, seek board representation, or propose changes to the issuer's capitalization or strategy, including its cryptocurrency treasury initiatives.